An intermediate effect size variant in UMOD confers risk for chronic kidney disease
Eric Gregory Olinger, Céline Schaeffer, Kendrah O. Kidd, Elhussein A. E. Elhassan, Yurong Cheng, Inès Dufour, Guglielmo Schiano, Holly R. Mabillard, Elena Pasqualetto, Patrick Hofmann, Daniel Guido Fuster, Andreas David Kistler, Ian Wilson, Stanislav Kmoch, Laure Raymond, , Magdalena Zarowiecki
The paper identifies an intermediate-effect variant in UMOD associated with chronic kidney disease risk and shows it has reduced disease severity compared to canonical ADTKD mutations.
Proceedings of the National Academy of Sciences · Aug 10, 2022Peer-reviewedGenetic & Genomic Medicine